NEWTON, Mass. and FLORENCE, Italy, Oct. 31, 2022 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group (“Menarini”), a privately-held, leading international pharmaceutical company,… Click here to view original post… […]
A Dana-Farber clinical trial of a so-called antibody-drug conjugates shows promising results for a Roxbury resident battling metastatic breast cancer. Click here to view original post… […]
First large genetic study of bipolar disorder in Asian populations launches Click here to view original post… […]
Coming off a strong third quarter, Waltham medical device giant Thermo Fisher Scientific Inc. is deploying some of its cash to buy a U.K. diagnostics firm. Click here to view original post… […]
DANVERS, Mass.–(BUSINESS WIRE)–Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure Click here to view original post… […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)– #CTAD2022–Cognito Therapeutics, a clinical-stage company pioneering disease-modifying therapeutic interventions for neurodegenerative diseases, announced today it has been selected to present clinical data from its proprietary gamma sensory stimulation in patients with Alzheimer’s Disease, at the 2022 Clinical Trials in Alzheimer’s Disease (CTAD), held November 29 – December… Click here to view original post… […]
WALTHAM, Mass.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today provided an update on capital deployment. Throughout the fourth quarter of 2022, Thermo Fisher expects to execute a $1.0 billion share repurchase program, bringing the total capital deployed on buybacks to $3.0 billion… Click here to view original post… […]
WALTHAM, Mass.–(BUSINESS WIRE)–Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has entered into a definitive agreement to acquire The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics, from a shareholder group led by European private equity… Click here to view original post… […]
CAMBRIDGE, Mass., Oct. 31, 2022 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that it has commenced an underwritten public offering… Click here to view original post… […]
CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)—- $KALV–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced positive phase 1 data for an orally disintegrating tablet (ODT) formulation for its lead compound sebetralstat. Sebetralstat is currently… Click here to view original post… […]
Copyright © 2023 Biotech Networks, LLC
